T-3PY058739 is under clinical development by T3 Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how T-3PY058739’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

T-3PY058739 overview

T-3PY058739 is under development for the treatment of solid tumor. The drug candidate is genetically modified organism (GMO) consisting engineered live bacteria developed based on protein delivery platform. It acts by targeting type 1 interferon and TLR. It is administered through intravenous and intratumor route.

T3 Pharmaceuticals overview

T3 Pharmaceuticals, is a pre-clinical biopharmaceutical company that develops specific therapies for cancer patients. The company is headquartered in Switzerland.

For a complete picture of T-3PY058739’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.